Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$30,000.00
Oct 2, 2023
For-profit organization
Scientific and Business Analyst
1011033
• Develop the scientific rationale for pipeline elements, including generation of high-quality, detailed analyses and reports to support therapeutic indication selection and pipeline progression.
• Analyse market trends and competitor activities to inform business and R&D strategy and identify potential risks and opportunities.
• Analyse and interpret data derived from in house and external research studies to generate high-quality reports.
• Identify new business opportunities in the pharmaceutical and nutraceutical industry related to neurological diseases.
• Develop and maintain relationships with key industry stakeholders, including pharmaceutical companies, academic institutions, and government agencies.